Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Blood

Volumn 118, Issue 2, 2011, Pages 358-367

  Niederfellner, Gerhard ^a   Lammens, Alfred ^b   Mundigl, Olaf ^a   Georges, Guy J ^a   Schaefer, Wolfgang ^a   Schwaiger, Manfred ^a   Franke, Andreas ^a   Wiechmann, Kornelius ^a,c   Jenewein, Stefan ^a   Slootstra, Jerry W ^d   Timmerman, Peter ^d   Brännström, Annika ^e   Lindstrom, Frida ^e   Mössner, Ekkehard ^f   Umana, Pablo ^f   Hopfner, Karl Peter ^b   Klein, Christian ^f  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d Pepscan Systems   (Netherlands)

^e Sidec Technologies AB   (Sweden)

^f Roche Glycart   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; OBINUTUZUMAB;

ARTICLE; BINDING AFFINITY; CELL COMPARTMENTALIZATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 79960497321     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-305847     Document Type: Article

References (15)

1. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823-3837. (Pubitemid 47332625)
2. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf. 2009;8(2):223-235.
3. Mössner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct- and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402.
4. Cragg MS, Morgan SM, Chan HTC, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045-1052. (Pubitemid 36139378)
5. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47(2):107-114.
6. Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119(8):2143- 2159.
7. Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody rituximab. J Biol Chem. 2007;282(20):15073-15080. (Pubitemid 47093338)
8. Du J, Wang H, Zhong C, et al. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide. Mol Immunol. 2008;45(10):2861-2868.
9. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood. 2002;99(9):3256-3262. (Pubitemid 34525305)
10. Teeling JL, Mackus WJM, Wiegman LJJM, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362-371. (Pubitemid 43939148)
11. Slootstra JW, Puijk WC, Ligtvoet GJ, Langeveld JP, Meloen RH. Structural aspects of antibody-antigen interaction revealed through small random peptide libraries. Mol Divers. 1996;1(2):87-96.
12. Banyay M, Gilstring F, Hauzenberger E, et al. Three-dimensional imaging of in situ specimens with low-dose electron tomography to analyze protein conformation. Assay Drug Dev Technol. 2004;2(5):561-567. (Pubitemid 39619099)
13. Johnson NA, Leach S, Woolcock B, et al. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica. 2009;94(3):423-427.
14. Stanfield RL, Zemla A, Wilson IA, Rupp B. Antibody elbow angles are influenced by their light chain class. J Mol Biol. 2006;357(5):1566-1574.
15. Du J, Yang H, Guo Y, Ding J. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009;46(11-12):2419-2423.